Xiaoying Wu

Nanjing, 210032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer.

BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 08, 2026

Glutamine Starvation Induces Ferroptosis in NSCLC via AMPK/PDZD8-Mediated Ferritinophagy.

Glutamine Starvation Induces Ferroptosis in NSCLC via AMPK/PDZD8-Mediated Ferritinophagy.

Journal: Nutrients

Published: March 30, 2026

Correction to: Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA.

Correction to: Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA.

Journal: BMC cancer

Published: January 27, 2026

Genomic Determinants and an Exploratory Prognostic Model for Immunotherapy Outcomes in Recurrent or Metastatic Cervical Cancer.

Genomic Determinants and an Exploratory Prognostic Model for Immunotherapy Outcomes in Recurrent or Metastatic Cervical Cancer.

Journal: The oncologist

Published: January 20, 2026

Novel Resistance Mechanisms to Second-Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC.

Novel Resistance Mechanisms to Second-Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC.

Journal: Genes, chromosomes & cancer

Published: August 12, 2025

Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA.

Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA.

Journal: BMC cancer

Published: June 08, 2025

Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non-small cell lung cancer.

Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non-small cell lung cancer.

Journal: Cancer

Published: April 24, 2025

Genomic signatures in plasma circulating tumor DNA reveal treatment response and prognostic insights in mantel cell lymphoma.

Genomic signatures in plasma circulating tumor DNA reveal treatment response and prognostic insights in mantel cell lymphoma.

Journal: Cancer cell international

Published: February 28, 2025

Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial.

Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial.

Journal: Molecular cancer

Published: January 25, 2025

Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers.

Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers.

Journal: BMC medicine

Published: September 28, 2024

Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions.

Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions.

Journal: BMC medicine

Published: September 15, 2024

Molecular characterization and biomarker identification in paediatric B-cell acute lymphoblastic leukaemia.

Molecular characterization and biomarker identification in paediatric B-cell acute lymphoblastic leukaemia.

Journal: Journal of cellular and molecular medicine

Published: June 23, 2024

Showing 1-12 of 21

Last Updated: 09/26/2026